Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2010

01-05-2010 | Letter

Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells

Authors: K. Müller, C. Weidinger, D. Führer

Published in: Diabetologia | Issue 5/2010

Login to get access

Excerpt

To the Editor: The mitogenic potency of the analogous insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is currently under heated debate [1], since several clinical studies have raised the possibility of insulin glargine treatment having a carcinogenic potential, especially in breast cancer [2]. Moreover, latest data from Shukla et al. [3] suggest that insulin glargine may indeed trigger cellular proliferation in MCF-7 breast cancer cells at lower dosages than normal insulin. …
Literature
1.
Stumvoll M, Nawroth PP (2009) The insulin glargine dilemma: an opportunity for the diabetes community? Diabetologia 52:1987–1989CrossRefPubMed
2.
Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia 52:1745–1754CrossRefPubMed
3.
Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441CrossRefPubMed
4.
Riesco-Eizaguirre G, Santisteban P (2007) Molecular biology of thyroid cancer initiation. Clin Transl Oncol 9:686–693CrossRefPubMed
5.
Karger S, Weidinger C, Krause K et al (2009) FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 16:189–199CrossRefPubMed
6.
Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D (2008) Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer 15:917–929CrossRefPubMed
7.
Guigon CJ, Zhao L, Willingham MC, Cheng SY (2009) PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28:509–517CrossRefPubMed
8.
Weng LP, Gimm O, Kum JB et al (2001) Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet 10:251–258CrossRefPubMed
Metadata
Title
Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells
Authors
K. Müller
C. Weidinger
D. Führer
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1674-3

Other articles of this Issue 5/2010

Diabetologia 5/2010 Go to the issue

Article

Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus—review and meta-analysis

Article

The impact of liver fat vs visceral fat in determining categories of prediabetes

Article

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care

Commentary

Diabetes therapy and cancer risk: causal effects and other plausible explanations

Article

Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells

Letter

Sulphated galactosylceramide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits